Actinium positioned for takeout after Fusion deal, says H.C. Wainwright

H.C. Wainwright says acquisitions in the radiopharma sector, including AstraZeneca’s (AZN) deal today to buy its partner in radiopharmaceuticals, Fusion Pharma (FUSN), for an upfront value of $2.0B in cash underscores Actinium Pharmaceuticals’ (ATNM) potential and business development prospects. A deal of this size underscores the continued interest in the radiopharmaceutical space as a whole, says the analyst, who sees a positive read-through for Actinium in particular. Actinium is well positioned “for a similar takeout route,” contends H.C. Wainwright. The firm has a Buy rating on the shares with a $50 price target. The stock in morning trading is up 20% to $7.86.